Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.

"Declaration of personal interests: A. Sidney Barritt 4th conducts NASH‐related clinical trials with support from Intercept, Genfit, Allergan, Celgene, Galmed, Pfizer, Bristol Myers Squibb, Viking and Gilead. He has provided consulting for Intercept and Target RWE in the past 12 months. Emma Marshman received funding from Novo Nordisk Inc. for medical writing support for this manuscript. Mazen Noureddin has served on the advisory boards for 89BIO, Gilead, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Terns, Perspectum, Siemens and Roche Diagnostic. He has received research support from Allergan, Bristol Myers Squibb, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Shire, Viking and Zydus. He is a minor shareholder and has stocks in Anaetos, Rivus Pharma and Viking."

"Funding information This article was supported by Novo Nordisk Inc., who performed a medical accuracy review. Writing support was provided by Emma Marshman, a contract writer working on behalf of Axis, a division of Spirit Medical Communications Group Limited, and was funded by Novo Nordisk Inc. in accordance with Good Publication Practice 3 (GPP3) guidelines ( www.ismpp.org/gpp3 ). Emma Marshman and Laura Ward, a former employee of Axis, a division of Spirit Medical Communications Group Limited, performed the literature review, funded by Novo Nordisk Inc."